164 related articles for article (PubMed ID: 16436498)
1. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice.
Nicholson JR; Kohler G; Schaerer F; Senn C; Weyermann P; Hofbauer KG
J Pharmacol Exp Ther; 2006 May; 317(2):771-7. PubMed ID: 16436498
[TBL] [Abstract][Full Text] [Related]
2. Role of the central melanocortin system in cachexia.
Marks DL; Ling N; Cone RD
Cancer Res; 2001 Feb; 61(4):1432-8. PubMed ID: 11245447
[TBL] [Abstract][Full Text] [Related]
3. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist.
Markison S; Foster AC; Chen C; Brookhart GB; Hesse A; Hoare SR; Fleck BA; Brown BT; Marks DL
Endocrinology; 2005 Jun; 146(6):2766-73. PubMed ID: 15774557
[TBL] [Abstract][Full Text] [Related]
4. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.
Joppa MA; Gogas KR; Foster AC; Markison S
Peptides; 2007 Mar; 28(3):636-42. PubMed ID: 17204351
[TBL] [Abstract][Full Text] [Related]
5. MC4 receptor antagonists: a potential treatment for cachexia.
Foster AC; Chen C; Markison S; Marks DL
IDrugs; 2005 Apr; 8(4):314-9. PubMed ID: 15800806
[TBL] [Abstract][Full Text] [Related]
6. Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model.
Vos TJ; Caracoti A; Che JL; Dai M; Farrer CA; Forsyth NE; Drabic SV; Horlick RA; Lamppu D; Yowe DL; Balani S; Li P; Zeng H; Joseph IB; Rodriguez LE; Maguire MP; Patane MA; Claiborne CF
J Med Chem; 2004 Mar; 47(7):1602-4. PubMed ID: 15027849
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor.
Tran JA; Jiang W; Tucci FC; Fleck BA; Wen J; Sai Y; Madan A; Chen TK; Markison S; Foster AC; Hoare SR; Marks D; Harman J; Chen CW; Arellano M; Marinkovic D; Bozigian H; Saunders J; Chen C
J Med Chem; 2007 Dec; 50(25):6356-66. PubMed ID: 17994683
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists.
Chen C; Tucci FC; Jiang W; Tran JA; Fleck BA; Hoare SR; Wen J; Chen T; Johns M; Markison S; Foster AC; Marinkovic D; Chen CW; Arellano M; Harman J; Saunders J; Bozigian H; Marks D
Bioorg Med Chem; 2008 May; 16(10):5606-18. PubMed ID: 18417348
[TBL] [Abstract][Full Text] [Related]
9. Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia.
Gelin J; Andersson C; Lundholm K
Cancer Res; 1991 Feb; 51(3):880-5. PubMed ID: 1988128
[TBL] [Abstract][Full Text] [Related]
10. Central administration of peptide and small molecule MC4 receptor antagonists induce hyperphagia in mice and attenuate cytokine-induced anorexia.
Joppa MA; Ling N; Chen C; Gogas KR; Foster AC; Markison S
Peptides; 2005 Nov; 26(11):2294-301. PubMed ID: 16269355
[TBL] [Abstract][Full Text] [Related]
11. Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells.
Argilés JM; Figueras M; Ametller E; Fuster G; Olivan M; de Oliveira CC; López-Soriano FJ; Isfort RJ; Busquets S
Muscle Nerve; 2008 Feb; 37(2):190-5. PubMed ID: 17912749
[TBL] [Abstract][Full Text] [Related]
12. 4-{(2R)-[3-Aminopropionylamido]-3-(2,4-dichlorophenyl)propionyl}-1-{2-[(2-thienyl)ethylaminomethyl]phenyl}piperazine as a potent and selective melanocortin-4 receptor antagonist--design, synthesis, and characterization.
Chen C; Pontillo J; Fleck BA; Gao Y; Wen J; Tran JA; Tucci FC; Marinkovic D; Foster AC; Saunders J
J Med Chem; 2004 Dec; 47(27):6821-30. PubMed ID: 15615531
[TBL] [Abstract][Full Text] [Related]
13. Differential role of melanocortin receptor subtypes in cachexia.
Marks DL; Butler AA; Turner R; Brookhart G; Cone RD
Endocrinology; 2003 Apr; 144(4):1513-23. PubMed ID: 12639936
[TBL] [Abstract][Full Text] [Related]
14. Provision of rhIGF-I/IGFBP-3 complex attenuated development of cancer cachexia in an experimental tumor model.
Wang W; Iresjö BM; Karlsson L; Svanberg E
Clin Nutr; 2000 Apr; 19(2):127-32. PubMed ID: 10867731
[TBL] [Abstract][Full Text] [Related]
15. Anticatabolic properties of melanocortin-4 receptor antagonists.
Madison LD; Marks DL
Curr Opin Clin Nutr Metab Care; 2006 May; 9(3):196-200. PubMed ID: 16607116
[TBL] [Abstract][Full Text] [Related]
16. Effect of c-ski overexpression on the development of cachexia in mice bearing the Lewis lung carcinoma.
Carbó N; Costelli P; Busquets S; López-Soriano J; López-Soriano FJ; Baccino FM; Argilés JM
Int J Mol Med; 2004 Oct; 14(4):719-23. PubMed ID: 15375607
[TBL] [Abstract][Full Text] [Related]
17. Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice.
Cheung WW; Kuo HJ; Markison S; Chen C; Foster AC; Marks DL; Mak RH
J Am Soc Nephrol; 2007 Sep; 18(9):2517-24. PubMed ID: 17687077
[TBL] [Abstract][Full Text] [Related]
18. Comparison of animal models for head and neck cancer cachexia.
Cannon T; Couch M; Yin X; Guttridge D; Lai V; Shores C
Laryngoscope; 2007 Dec; 117(12):2152-8. PubMed ID: 17921906
[TBL] [Abstract][Full Text] [Related]
19. Multiple organ failure of tumor-bearing rabbits in cancer cachexia is caused by apoptosis of normal organ cells.
Fukuda T; Sumi T; Nobeyama H; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Oncol; 2009 Jan; 34(1):61-7. PubMed ID: 19082478
[TBL] [Abstract][Full Text] [Related]
20. Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states.
Nickolls SA; Fleck B; Hoare SR; Maki RA
J Pharmacol Exp Ther; 2005 Jun; 313(3):1281-8. PubMed ID: 15743921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
